1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Se-cure Pharmaceuticals Ltd. - Product Pipeline Review - 2013

Se-cure Pharmaceuticals Ltd. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 20 pages

Se-cure Pharmaceuticals Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Se-cure Pharmaceuticals Ltd. - Product Pipeline Review - 2013” provides data on the Se-cure Pharmaceuticals Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Se-cure Pharmaceuticals Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Se-cure Pharmaceuticals Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Se-cure Pharmaceuticals Ltd. - Brief Se-cure Pharmaceuticals Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Se-cure Pharmaceuticals Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Se-cure Pharmaceuticals Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Se-cure Pharmaceuticals Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Se-cure Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Se-cure Pharmaceuticals Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Se-cure Pharmaceuticals Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Se-cure Pharmaceuticals Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Se-cure Pharmaceuticals Ltd. and identify potential opportunities in those areas.

Table Of Contents

Se-cure Pharmaceuticals Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Se-cure Pharmaceuticals Ltd. Snapshot 4
Se-cure Pharmaceuticals Ltd. Overview 4
Key Information 4
Key Facts 4
Se-cure Pharmaceuticals Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Se-cure Pharmaceuticals Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Se-cure Pharmaceuticals Ltd. - Pipeline Products Glance 9
Se-cure Pharmaceuticals Ltd. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Se-cure Pharmaceuticals Ltd. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Se-cure Pharmaceuticals Ltd. - Drug Profiles 11
SC-012 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
SC-106 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
SC-661 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Se-cure Pharmaceuticals Ltd. - Pipeline Analysis 14
Se-cure Pharmaceuticals Ltd. - Pipeline Products by Therapeutic Class 14
Se-cure Pharmaceuticals Ltd. - Pipeline Products By Target 15
Se-cure Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 16
Se-cure Pharmaceuticals Ltd. - Pipeline Products By Mechanism of Action 17
Se-cure Pharmaceuticals Ltd. - Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20



List of Tables

Se-cure Pharmaceuticals Ltd., Key Information 4
Se-cure Pharmaceuticals Ltd., Key Facts 4
Se-cure Pharmaceuticals Ltd. - Pipeline by Indication, 2013 6
Se-cure Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2013 7
Se-cure Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2013 8
Se-cure Pharmaceuticals Ltd. - Phase I, 2013 9
Se-cure Pharmaceuticals Ltd. - Preclinical, 2013 10
Se-cure Pharmaceuticals Ltd. - Pipeline By Therapeutic Class, 2013 14
Se-cure Pharmaceuticals Ltd. - Pipeline By Target, 2013 15
Se-cure Pharmaceuticals Ltd. - Pipeline By Route of Administration, 2013 16
Se-cure Pharmaceuticals Ltd. - Pipeline Products By Mechanism of Action, 2013 17



List of Figures

Se-cure Pharmaceuticals Ltd. - Pipeline by Indication, 2013 6
Se-cure Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2013 7
Se-cure Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2013 8
Se-cure Pharmaceuticals Ltd. - Pipeline By Therapeutic Class, 2013 14
Se-cure Pharmaceuticals Ltd. - Pipeline By Route of Administration, 2013 16
Se-cure Pharmaceuticals Ltd. - Pipeline Products By Mechanism of Action, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.